Behind most compliant peptide programmes in the UAE sits a compounding pharmacy. This explainer covers what compounding actually is, who licenses it, how a compliant peptide prescription flows from consultation to delivery, and how operators build a business on top of that chain without owning a pharmacy.
What compounding is and when it applies
Compounding is the preparation of a medicine by a licensed compounding pharmacy for an individual patient, against a prescription from a licensed clinician. It exists for the cases where a stock product does not fit: a strength, combination, or format the prescriber decides an individual patient needs. In peptide medicine, where dosing is personalised, that is exactly why compounding carries so much of the category.
The definition also sets the limits. A compounded preparation is made for one named patient against one prescription. It is not a stock product, it is not marketed to the public, and it is never something a patient can buy or order directly. Compounding is a clinical mechanism for individual care, not a route around product registration for supply at scale.
Who licenses compounding in the UAE
MOHAP. When the UAE reorganised federal pharmaceutical regulation under the 2025 law, most functions moved to the Emirates Drug Establishment (EDE), but compounding pharmacy licensing stayed with the Ministry of Health and Prevention. The clinical operation in front is licensed separately: in Dubai, a telehealth facility holds a DHA licence, applied for through the Sheryan portal, with records in an EMR connected to NABIDH.
Three authorities, one chain
- MOHAP: compounding pharmacy licensing, alongside community pharmacy licensing and certain narcotics controls
- EDE: product classification, registration, import and export permits, and GDP oversight of the supply chain
- DHA: the telehealth facility and clinicians in front, licensed through Sheryan and connected to NABIDH
The distinction matters when structures are described. A compounding pharmacy is not a DHA facility: the pharmacy is MOHAP-licensed, and the DHA licenses the telehealth operation in front of it. Operators who blur the two in their documents, or in their marketing, are describing a structure that does not exist, and authorities notice.
How a compliant peptide prescription flows end to end
Put the licences in a row and the flow of a single compounded peptide prescription looks like this.
Consultation
A DHA-licensed clinician consults the patient through a DHA-licensed telehealth facility, and the encounter is documented in the NABIDH-connected EMR.
Prescription
The clinician holds the decision. If treatment is appropriate, a prescription is issued for that individual patient; if not, nothing moves.
Compounding
A MOHAP-licensed compounding pharmacy prepares the compounded medicine against that prescription, to the strength and format prescribed.
Cold chain
Peptides are temperature sensitive. Imported materials move under EDE import permits through a GDP medical warehouse, and the preparation travels under cold chain conditions.
Delivery
The medicine is dispensed and delivered to the patient through licensed channels, completing a chain in which every step is held by a licence.
The chain reads as clinical at the front and pharmaceutical at the back, and that is the point. Each handover, consultation to prescription, prescription to pharmacy, pharmacy to patient, happens between licensed parties, which is what makes the model auditable from either end.
What operators must never do
The failure modes in this category are well defined, and none of them is a grey area.
- Supplying peptides without a prescription from a licensed clinician, whatever the product or the channel
- Importing unregistered products outside the permit system: unregistered importation risks seizure and penalties
- Compounding, or arranging compounding, anywhere other than a MOHAP-licensed compounding pharmacy
- Marketing compounded preparations as stock products the public can buy or order directly
Each of these removes the licence that holds a step of the chain, and the chain is only as compliant as its weakest handover. The EDE also classifies each peptide product case by case, so the pathway must be confirmed per product before it appears on a treatment menu. The commercial logic follows the compliance logic: structures built on these rules keep operating, and structures built around them do not.
Building this as a business
None of this requires an operator to own the pharmacy layer. The working structure is a DHA-licensed telehealth operation in front, with MOHAP-licensed compounding pharmacy partners behind it and a registered supply chain underneath: EDE classification per product, licensed importation under our own importer credentials and EDE permits, a GDP medical warehouse, and licensed distribution.
We build that structure turnkey. The telehealth front end typically reaches an active DHA licence in approximately 45 to 60 days, subject to authority response times, with the compounding and supply arrangements run in parallel. The full structure is on our peptide business in the UAE page, and the clinical build is detailed on our telemedicine business setup page.
Explore the peptide business build
Frequently asked questions
Who licenses compounding pharmacies in the UAE?
Can a telehealth clinic compound its own peptides?
Are compounded peptides prescription-only in the UAE?
Do I need to own a compounding pharmacy to run a peptide programme?
This explainer is general information for operators and investors, not medical, legal, or regulatory advice. Compounded preparations are made by licensed pharmacies only against prescriptions from licensed clinicians for individual patients, and peptide products are classified by the EDE case by case. Confirm current rules with the relevant authority or your regulatory partner before acting.